MobileODT

Company Overview

Snapshot

Founded in October 2012, MobileODT operates with 1–10 employees. The company has raised a total of $22.48 million across 7 funding rounds from 6 investors. In January 2022, MobileODT announced the release of a next-generation AI algorithm for cervical cancer screening, signaling continued innovation in its core technology.

Business overview

MobileODT develops optical diagnostic devices and software services focused on early cancer detection and various medical applications. The company leverages advanced optical technology to transform smartphones into mobile point-of-care tools for cancer detection and biomedical image capture. Its product portfolio includes the FDA-cleared EVA COLPO, an internet-connected portable colposcope; EVA SANE, a forensic documentation system;. MobileODT serves the health tech and life sciences sectors, operating within digital healthcare and digital medical diagnostics, with a focus on healthcare providers.

Strategic signal

In January 2022, MobileODT released a next-generation AI algorithm for cervical cancer screening. This development is significant as it enhances the accuracy and efficiency of early detection, addressing a critical need in global women's health. For investors, this signals MobileODT's commitment to continuous innovation and its potential to strengthen its market position in AI-driven medical diagnostics.

Company Intelligence Q&A

What is MobileODT's primary focus?

MobileODT develops AI-based cervical cancer screening solutions, utilizing optical diagnostic devices and software services for early cancer detection and other medical purposes.

When was MobileODT founded?

MobileODT was founded in October 2012.

What significant product development did MobileODT announce in January 2022?

In January 2022, MobileODT announced the release of a next-generation AI algorithm for cervical cancer screening, enhancing its diagnostic capabilities.

Which grant did MobileODT receive in January 2021?

In January 2021, MobileODT was awarded a grant from the National Cancer Institute.

What was the outcome of MobileODT's participation in India's cervical cancer screening program?

In December 2021, MobileODT announced its participation in India's largest cervical cancer screening program, indicating its expanding global reach and impact.